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 Baeyer-Villiger monooxygenases (BVMO) are flavoenzymes that catalyze a remarkably wide variety of oxidative 
reactions such as regio- and enantioselective Baeyer-Villiger oxidations and sulfoxidations. Several of these 
conversions are difficult to achieve using chemical approaches. Due to their selectivity and catalytic efficiency, 
BVMOs are highly valuable biocatalysts for synthesis of a broad range of fine chemicals. For a long time, only one 
member of this class of flavin containing biocatalysts had been cloned and overexpressed which has limited their 
application for synthetic processes. Recently a number of new genes that encode BVMOs have been sequenced and 
overexpressed. In this paper the biocatalytic properties of recently cloned BVMOs will be reviewed. Furthermore, the 





 The conversion of ketones into esters or cyclic ketones into lactones was discovered more than 
a century ago by Adolf von Baeyer and Victor Villiger (Baeyer and Villiger, 1899). In this reaction, 
the ketone is attacked by a nucleophilic peroxy acid to form the so-called tetrahedral ‘Criegee 
intermediate’ (Scheme 1) (Criegee, 1948). This unstable species undergoes a rearrangement via 
expulsion of a carboxylate ion and migration of a carbon-carbon bond, yielding the ester and the 
acid. In general, the most substituted carbon center migrates with retention of configuration. Steric, 
conformational, and electronic factors have influence on the rate of rearrangement and the 
migration preferences. Migration is also influenced by the type of peroxy acid used (Renz and 
Meunier, 1999). These features make the Baeyer-Villiger reaction an interesting tool for the 




























Scheme 1.  Mechanism of the Baeyer-Villiger oxidation by peracids. 
 
 Unfortunately, the general use of peracids like 3-chloroperoxybenzoic acid or 
peroxotrifluoroacetic acid as reagents and the use of solvents has several disadvantages that do not 
match with the principles of green chemistry (Anastas et al., 2000). Firstly, due to the shock-
sensitivity and explosive character of peracids, large-scale reactions increase the potential risk for 
accidents. Secondly, the use of halogenated reagents and solvents is environmentally unfriendly. 
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Thirdly, peracids are powerful oxidative agents. Therefore laborious protection and deprotection 
steps are needed in synthesis in order to prevent by-product formation.  
 To avoid the use of peracids, transition-metal catalysts (Strukul, 1998) and organocatalytic 
compounds (Fukuda et al., 2001; Mazzini et al., 1996; Murahashi et al., 2002) have been developed 
which use hydrogen peroxide or oxygen as milder oxidant for the Baeyer-Villiger reaction. An even 
more ‘green’ method has recently been applied by Bolm et al. as they used compressed CO2 as a 
solvent, establishing Baeyer-Villiger oxidation of various ketones using oxygen as primary oxidant 
and benzaldehyde or pivalaldehyde as co-reductant (Bolm et al., 2002). Despite these efforts, the 
development of biocatalytic processes would be highly attractive for performing enantio- and 
regioselective Baeyer-Villiger oxidations in an environmentally benign way. 
 The first example of a biological Baeyer-Villiger reaction dealt with the biotransformation of 
steroids by fungi and was discovered in 1948 (Turfitt, 1948). Since then, Baeyer-Villiger oxidation 
steps have been found in biosynthetic pathways in many different organisms e.g.: aflatoxin 
synthesis in fungi (Townsend et al., 1982), synthesis of iridoids and steroids in plants (Damtoft et 
al., 1995; Winter et al., 1999), and toxin synthesis in shellfish (Wright et al., 1996). Baeyer-Villiger 
oxidation steps have also been frequently observed in microbial degradation pathways. 
Microorganisms have been found to use Baeyer-Villiger monooxygenases (BVMOs) in order to 
grow on aliphatic methyl ketones (Britton and Markovetz, 1977; Forney and Markovetz, 1969), 
alicyclic hydrocarbons (Donoghue and Trudgill, 1975; Griffin and Trudgill, 1976; Schumacher and 
Fakoussa, 1999), aromatic compounds (Casellas et al., 1997; Cripps, 1975; Cripps et al., 1978; 
Darby et al., 1987; Havel and Reineke, 1993; Higson and Focht, 1990; Hopper et al., 1985; Jones et 
al., 1994), and terpenes (Ougham et al., 1983; van der Werf and Boot, 2000). 
 All BVMOs characterized to date are NAD(P)H-dependent flavoproteins. They incorporate one 
atom of molecular oxygen into the substrate and the other atom is reduced to water. BVMOs can be 
classified in two groups: Type I BVMOs contain flavin adenine dinucleotide (FAD) as cofactor, use 
NADPH as source for electrons and consist of identical subunits, while Type II BVMOs contain 
flavin mononucleotide (FMN) as cofactor, use NADH as electron donor and are composed of α2β 
trimers (Willetts, 1997). So far, all BVMOs that have been cloned could be classified as Type I 
enzymes while no Type II BVMO sequence is known. Unfortunately, there are no crystal structures 
available of any BVMO that would disclose the structural features of this class of enzymes. 
 Since their discovery much research has been performed to explore the biocatalytic properties 
of BVMOs, either using whole-cells or isolated enzymes. BVMOs are able to catalyze a remarkable 
wide variety of oxidative reactions such as regio- and enantioselective Baeyer-Villiger oxidations 
and sulfoxidations, reactions which are difficult, if not impossible, to be achieved using chemical 
approaches (see reviews (Colonna et al., 1996; Flitsch and Grogan, 2002; Mihovilovic et al., 
2002b; Roberts and Wan, 1998; Walsh and Chen, 1988; Willetts, 1997)). However, until a few 
years ago only one BVMO, cyclohexanone monooxygenase (CHMO; EC 1.14.13.22), had been 
cloned and overexpressed, which limited application of this type of biocatalyst for synthetic 
processes. 
 In this review we will focus on the biocatalytic properties of newly identified and characterized 
Type I BVMOs. Except for the discovery of several CHMO homologues, a number of BVMOs 
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exhibiting novel substrate profiles have been characterized. As all these newly reported BVMOs 
share sequence homology with CHMO, some recent findings concerning this well-known 
biocatalyst will be discussed first. Then, we will summarize the biocatalytic properties of 
cyclopentanone monooxygenase (CPMO; EC 1.14.13.16) (Iwaki et al., 2002), cyclododecanone 
monooxygenase (CDMO; EC 1.14.13.x) (Kostichka et al., 2001), steroid monooxygenase (SMO; 
EC 1.14.13.54) (Morii et al., 1999), and 4-hydroxyacetophenone monooxygenase (HAPMO; EC 
1.14.13.x) (Kamerbeek et al., 2001). Special attention will be given to HAPMO: a BVMO that is 
primarily active with aromatic compounds. In addition, we will emphasize the potential of novel 
Type I BVMOs which can be obtained by in silico screening of sequenced genomes. Finally, we 
will discuss other sources for Baeyer-Villiger oxidation biocatalysts. 
 
 
2. AVAILABLE RECOMBINANT BVMOs 
 
2.1 Cyclohexanone monooxygenase (CHMO) 
 CHMO from Acinetobacter NCIB 9871 is the most studied Type I BVMO regarding its 
biocatalytic properties and for a long time this enzyme was the only BVMO of which the gene had 
been cloned (Y. C. Chen et al., 1988). The CHMO sequence deposited later by Iwaki et al. (Iwaki 
et al., 1999b) differed from that originally reported by Chen et al. at several nucleotide positions 
(Cheesman et al., 2001). Recent mass spectrometry experiments proved that the sequence deposited 
by Iwaki et al. is the correct CHMO sequence (Kneller et al., 2001). The CHMO gene encodes a 
60.9 kDa protein appearing as monomer upon purification (Table 1). Recently, six other 
cyclohexanone monooxygenase genes were identified (Brzostowicz et al., 2000; Brzostowicz et al., 
2003; Cheng et al., 2000). All these newly identified CHMOs show significant protein sequence 
identity with CHMO from Acinetobacter NCIMB 9871. While activity with cyclohexanone has 
been demonstrated for these novel CHMOs, their biocatalytic potential has not yet been fully 
explored. 
 The catalytic mechanism of CHMO has been studied with rapid reaction techniques and 
proceeds as follows (Ryerson et al., 1982; Sheng et al., 2001). First, the protein-bound FAD is 
reduced by NADPH, generating the reduced enzyme-NADP+ complex. In the next step, this binary 
complex reacts with oxygen to form a flavin-peroxide species, which undergoes a nucleophilic 
attack on the carbonyl group of the ketone substrate. The Criegee intermediate thus formed 
rearranges to the ester product with concomitant formation of a flavin-hydroxide. Finally, water is 
eliminated from the latter species to reform oxidized FAD and release of NADP+ completes the 
catalytic cycle (Scheme 2). The ambivalent character of the peroxyflavin is thought to account for 
the capability of CHMO to catalyze the conversion of both electron-rich and electron-deficient 
substrates (Walsh and Chen, 1988). The electrophilic hydroperoxyflavin catalyzes asymmetric 
sulfoxidation of various thioethers (G. Chen et al., 1999), oxidation of amines (Colonna et al., 
2003; Ottolina et al., 1999), and oxidation of selenides (Walsh and Chen, 1988) (Scheme 2). The 




Table 1. Biochemical properties of the characterized Type I BVMOs.  
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the observed boron oxidation reactions (Branchaud and Walsh, 1985). The recently reported 
CHMO-mediated asymmetric epoxidation reactions were also suggested to proceed via the 
nucleophilic peroxyflavin species (Colonna et al., 2002), although it has been proposed that the 
electrophilic hydroperoxyflavin could catalyze epoxidation reactions (Branchaud and Walsh, 1985). 
 Numerous experiments, either with (engineered) whole-cells or isolated enzyme, have shown 
that CHMO is a useful biocatalyst for the synthesis of interesting compounds like (bicyclic) 
lactones (Stewart, 1998b), various sulfoxides (G. Chen et al., 1999; Colonna et al., 1996), cyclic 
sulfates (Colonna et al., 1998) and thiosulfinates (Colonna et al., 2001). CHMO displays a 
remarkable broad substrate specificity allowing conversion of a large variety of ketones and hetero-
atom containing compounds. For a number of reactions, the enzyme is highly enantioselective. 
Recently, it was shown that CHMO can even be used for performing a dynamic kinetic resolution 
process (Berezina et al., 2002) complying to the need of transformations with (theoretically) 100% 
yield and 100% ee (Strauss et al., 1999). In total, more than 100 substrates have been reported for 
CHMO. A comprehensive overview on reported CHMO-mediated Baeyer-Villiger reactions was 
recently published by Mihovilovic and coworkers (Mihovilovic et al., 2002b). 
 Because CHMO is strictly NADPH-dependent, the use of isolated enzyme for large-scale 
synthesis would require an efficient coenzyme recycling system, as NADPH is too expensive to use 
in stoichiometric amounts (Hummel, 1999). A well-known NADPH recycling system is the 
glucose-6-phosphate/glucose-6-phosphate dehydrogenase couple, but the high cost of glucose-6-
phosphate is a disadvantage. A cheaper alternative is the formate/formate dehydrogenase system. 
Two formate dehydrogenases from Pseudomonas sp. 110 (Tishkov et al., 1993) and Saccharomyces 
cerevisiae (Serov et al., 2002) have been engineered from NAD+ towards NADP+ preferring 
enzymes. The Pseudomonas enzyme has been used in combination with CHMO-catalyzed 
conversions (Rissom et al., 1997; Schwarz-Linek et al., 2001). Zambianchi et al. tested different 
NADPH regeneration systems and found optimal results with 2-propanol/alcohol dehydrogenase 
from Thermoanaerobium brockii (Zambianchi et al., 2002). An alternative approach for coenzyme 
recycling is represented by electrochemical regeneration of coenzymes (Somers et al., 1997). For 
example, the pentamethylcyclopentadienyl rhodium bipyridine complex [Cp*Rh(bpy)(H2O)]2+ is 
reduced by electrons from the cathode and takes up a proton yielding [Cp*Rh(bpy)H]+ which acts 
as a hydride transfer reagent on NAD(P)+. This system has successfully been used for synthetic 
application of a NADH-dependent monooxygenase (Hollmann et al., 2001; Hollmann et al., 2002). 
 Although isolated enzymes have certain advantages, whole-cell conversions with oxygenases 
are attractive for several reasons (Duetz et al., 2001). One major advantage is the efficient 
intracellular coenzyme regeneration. Furthermore, in case of CHMO, heterologous expression 
circumvents the problem of the lactone hydrolase activity present in the wild-type strain and by this, 
handling of the pathogenic Acinetobacter strain can be avoided. With this in mind, two different 
Escherichia coli strains have been engineered to overexpress CHMO (G. Chen et al., 1999; S.D. 
Doig et al., 2001) and expression in yeast has also been established (Cheesman et al., 2001; Stewart 
et al., 1996). Whole-cell conversions using recombinant CHMO-containing E. coli cells has been 
optimized and applied by Walton and Stewart (Walton and Stewart, 2002), who efficiently 
converted cyclohexanone into ε-caprolactone. Furthermore, Doig et al. (S. D. Doig et al., 2002), in 
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collaboration with partners from the chemical industry, scaled-up CHMO-mediated whole-cell 
conversion of the ketone bicyclohept-2-en-6-one (Figure 1, compound 1). The obtained 2-
oxabicyclo-oct-6-en-3-one lactones are valuable intermediates for synthesis of prostaglandins 
















































































Figure 1.. Some representative substrates for cyclohexanone monooxygenase, cyclopentanone 
monooxygenase and 4-hydroxyacetophenone monooxygenase highlighting the overlapping substrate 




2.2 Cyclopentanone monooxygenase (CPMO) 
 CPMO was purified in 1976 by Griffin et al. from Comamonas (previously Pseudomonas) sp. 
NCIMB 9872 growing on cyclopentanone (Griffin and Trudgill, 1976). Last year a gene cluster 
involved in cyclopentanone catabolism of this microorganism was characterized, and the gene 
encoding CPMO was cloned and expressed in E. coli (Iwaki et al., 2002). In contrast with CHMO, 
being a monomer, CPMO appears as a tetramer upon purification. The subunit molecular mass is 
62.1 kDa (Table 1).  
 Most biocatalytic studies with CPMO have been performed with whole-cells (Bes et al., 1996; 
Kelly et al., 1996; Sandey and Willetts, 1989). Initial tests showed that the enzyme prefers C4 to C8 
ketones and norbornanone (2) as substrates (Griffin and Trudgill, 1976). These compounds are also 
oxidized by CHMO indicating that the substrate specificities of these two BVMOs overlap (Figure 
1). Although several substrates can be converted by both CPMO and CHMO, the enantioselectivity 
can differ. For example, the prochiral compound 4-methylcyclohexanone (3, R = CH3) is converted 
by CHMO to the (S)-lactone whereas CPMO produces the (R)-lactone (Iwaki et al., 2002). Another 
example is the conversion of racemic 2-substituted cyclopentanones (4). While the CPMO-
catalyzed conversions of these cyclopentanones are non-enantioselective (Iwaki et al., 2002), 
CHMO shows high enantioselectivity with these compounds, enabling kinetic resolution (Kayser et 
al., 1998). On the other hand, successful enantioselective oxidation of an unsaturated cyclic ketone, 
5-hexyl-2-cyclopentenone and of 2-(2’-acetoxyethyl)cyclohexanones was reported for CPMO (Bes 
et al., 1996). These conversions are of interest because many functionalized chiral δ-valerolactones 
are biologically active compounds and valuable intermediates in natural product synthesis (Coutrot 
et al., 1999). 
 CPMO is also able to catalyze oxidation of the prochiral fused system (5) forming the opposite 
enantiomer to that obtained with CHMO (Mihovilovic et al., 2002; Mihovilovic et al., 2002b). 
Comparison of CHMO and CPMO also showed that several CPMO substrates are not accepted by 
CHMO. While the non-conjugated indan-2-one (6) is converted by both CHMO and CPMO, indan-
1-one and 5-methoxy-indan-1-one (7,8) could only be converted by CPMO (Iwaki et al., 2002). The 
same result was recently found by Furstoss and co-workers who tested various substituted 1-
indanones with whole cells expressing CHMO, CPMO or HAPMO. Only CPMO-expressing cells 
converted some of the tested indanones (Gutierrez et al., 2003). Also 4-methyl-4-n-
propylcyclohexanone (9) is only a substrate for CPMO (Iwaki et al., 2002). This clearly indicates 
that the substrate acceptance of CPMO broadens the scope of Baeyer-Villiger reactions that can be 
performed using recombinant enzymes. 
 
 
2.3 Cyclododecanone monooxygenase (CDMO) 
 Alicyclic hydrocarbons, like cyclopentane, cyclohexane and cyclododecane, are major 
components of petroleum. Baeyer-Villiger oxidation is one of the first steps in the microbial 
degradation of these compounds (Cheng et al., 2002). In 1999, the first cyclododecanone 
monooxygenase (CDMO) from Rhodococcus ruber CD4 was purified and characterized 
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(Schumacher and Fakoussa, 1999). From another strain, Rhodococcus ruber SC1, a gene cluster 
involved in cyclododecanone oxidation has been identified and the gene encoding CDMO was 
cloned and expressed in E. coli (Kostichka et al., 2001). From the protein sequence it can be 
deduced that CDMO from R. ruber SC1 is a 67.5 kDa protein (Table 1). Expression of CDMO 
enabled the use of whole cells for CDMO-mediated bioconversions. These experiments showed that 
CDMO efficiently converts C11-C15 cyclic ketones. Insignificant conversion was observed with C6 
and C10 cyclic ketones and the enzyme was inactive towards C7 and C8 cyclic ketones (Kostichka et 
al., 2001). By accepting bulky aliphatic cyclic ketones, compounds that are not accepted by CPMO 
and CHMO, this novel BVMO can be of great biocatalytic value. For example, CDMO is a suitable 
biocatalyst to produce lauryl lactone (Table 1), a compound for which a chemical synthesis route is 
not known (Thomas et al., 2002). 
 
 
2.4 Steroid monooxygenase (SMO) 
 As mentioned in the introduction, the first discovered BVMO activities involved microbial 
conversion of steroids (Turfitt, 1948). Two steroid monooxygenases performing Baeyer-Villiger 
reactions have been purified and characterized (Itagaki, 1986; Miyamoto et al., 1995). These SMOs 
from Cylindrocarpon radicicola and Rhodococcus rhodochrous have different substrate 
specificities. Whereas the Rhodococcus enzyme only catalyzes the esterification of the progesterone 
side-chain towards testosterone acetate (Table 1), the fungal enzyme also catalyzes oxidative 
lactonization of androstenedione to testololactone (Itagaki, 1986). A recombinant expression system 
for R. rhodochrous SMO has been constructed in E. coli (Morii et al., 1999). This resulted in a 40-
fold higher protein production compared to the level in R. rhodochrous. Some biochemical 
characteristics of SMO are listed in Table 1. Because no further biocatalytic studies have been 
reported for this BVMO, it would be worthwhile to test other substrates. While SMO has evolved to 
catalyze oxidations of steroids, it might also be able to convert compounds unrelated to its 
physiological substrate as has been observed for CHMO. Such promiscuity in substrate specificity 
has also been found for another flavoprotein acting on steroids: cholesterol oxidase from 
Rhodococcus erythropolis. This FAD containing oxidase was found to be able to perform 
enantioselective oxidations of a range of secondary alcohols (Biellmann, 2002). 
 
 
2.5  4-Hydroxyacetophenone monooxygenase (HAPMO) 
 Microbial Baeyer-Villiger oxidation of aromatic compounds was first reported in the mid 70’s 
(Cripps, 1975). Several of these aromatic degradation pathways involving Baeyer-Villiger oxidation 
have been elucidated which include the catabolic routes for acetophenones (Cripps, 1975; Cripps et 
al., 1978; Havel and Reineke, 1993; Higson and Focht, 1990), 1-phenyl ethanol (Cripps et al., 
1978), 4-ethylphenol (Jones et al., 1994), and fluorine (Casellas et al., 1997). The first purification 
of a BVMO active on aromatic compounds was only described in 1999 (Moonen et al., 1999). This 
enzyme, 4-hydroxyacetophenone monooxygenase (HAPMO), was isolated from Pseudomonas 
fluorescens ACB growing on 4-hydroxyacetophenone (Table 1) (Higson and Focht, 1990). 
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Recently, also a HAPMO homologue from Pseudomonas putida JD1, an organism growing on 4-
ethylphenol which is degraded via 4-hydroxyacetophenone, has been purified and characterized 
(Tanner and Hopper, 2000). HAPMO from P. fluorescens ACB is a homodimer of 144 kDa with 
each subunit containing a tightly non-covalently bound FAD. In P. fluorescens ACB, the enzyme 
oxidizes 4-hydroxyacetophenone towards 4-hydroxyphenyl acetate. The enzyme has a strong 
preference for NADPH over NADH, as has been found for all BVMOs described above, and is 
optimally active around pH 8. In 2001, the HAPMO encoding gene (hapE) was cloned which 
allowed overexpression of the recombinant biocatalyst in E. coli (Kamerbeek et al., 2001). The 
hapE gene is the fifth gene in an operon encoding the genes involved in the degradation of 
4-hydroxyacetophenone in P. fluorescens ACB. The fourth gene (hapD) encodes the 4-
hydroxyphenyl acetate hydrolase (Kamerbeek et al., 2001). 
 Initially, it was found that the substrate specificity of HAPMO covers a wide range of aryl 
ketones with a preference for compounds bearing an electron-donating substituent at the para-
position of the aromatic ring (Kamerbeek et al., 2001). Further studies revealed that HAPMO is 
also capable of catalyzing the Baeyer-Villiger oxidation of a wide variety of other ketones including 
several heteroaromatic and aliphatic compounds (Figure 1), while also some sulfides were shown to 
be readily converted (Kamerbeek et al., 2003). Being the first recombinant BVMO that acts 
primarily on aromatic compounds, HAPMO represents a promising biocatalytic tool as will be 
exemplified below. 
 Chemical synthesis of a phenol- or catechol-containing compound often requires protection of 
the hydroxyl group(s) to prevent oxidation reactions. For this, ethers are the most widely used 
protective groups, while esterification is an important alternative (Greene and Wuts, 1999). The 
HAPMO-catalyzed conversion of ring-substituted aryl ketones into their corresponding phenyl 
acetates provides a biocatalytic alternative for the synthesis of protected phenols and partially 
















Scheme 3. Biocatalytic production of protected catechols using HAPMO. 
 
Substituted catechols are valuable precursors for the synthesis of pharmaceutical compounds (Held 
et al., 1999; Husken et al., 2001; Wouters et al., 1988). Synthesis of these compounds requires the 
use of purified enzyme because with whole cells, the presence of a highly active esterase in P. 
fluorescens ACB prevents the accumulation of the desired products. Alternatively, E. coli cells that 
overexpress HAPMO can be used. Recent 19F NMR studies also showed that the rate of the 
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HAPMO-mediated conversion of 4-fluoracetophenones is optimal at pH 8 but that the fluorophenyl 
acetates are better stabilized at pH 6 (Moonen et al., 2001). 
 HAPMO is also able to perform a Baeyer-Villiger oxidation of 4-hydroxybenzaldehyde. Only 
the ester is formed indicating that, as observed for the conversion of aryl ketones, the aromatic ring 
is the migrating group. Enzymatic or chemical hydrolysis of the substituted phenyl acetates formed 
by HAPMO oxidation of aryl ketones or benzaldehydes gives access to substituted phenols and 
dihydroxybenzenes. This biocatalytic route can be exploited for producing 18F-fluorophenols from 
the corresponding 18F labeled aldehyde or ketone precursors. These fluorinated phenols find 
applications as radiotracers for positron emission tomography (PET) (Ekaeva et al., 1995). 
Substituted phenols obtained by chemical Baeyer-Villiger oxidation of aromatic aldehydes can also 
be used as building blocks for the synthesis of different coumestans, which are biologically active 
flavonoids (da Silva et al., 2001). Furthermore, hydrolysis of 4-hydroxyphenyl acetate affords 
hydroquinone, which is like other dihydroxybenzenes, an important intermediate of organic 
synthesis (Ivanov et al., 2002). Because chemical methods to synthesize hydroquinone use volatile 
and carcinogenic benzene as starting material, there is a growing interest in alternative routes to 
produce hydroquinone (Ran et al., 2001). 
 It has also been found that HAPMO can be used to produce chiral sulfoxides. Enantiomerically 
pure sulfoxides are of high interest for synthetic chemists as they influence the stereoselectivity of 
reactions at nearby centers (Carreno, 1995). HAPMO performs highly enantioselective oxidation of 
methyl phenyl sulfide (10) and methyl p-tolyl sulfide (Kamerbeek et al., 2003). Interestingly, 
compared to CHMO and CPMO, HAPMO shows a better performance in methyl p-tolyl sulfide 
oxidation (Table 2). 
 




HAPMO (Kamerbeek et 
al., 2003a) 
 
CHMO (Carrea et al., 
1992) 
 
CPMO (Kelly et 




methyl phenyl sulfide 
 
> 99 % (S) 
 
99 % (R) 
 




methyl p-tolyl sulfide 
 
> 99 % (S) 
 
37 % (S) 
 






[a] Experiments performed with whole cells. 
 
 In contrast to CHMO (Alphand et al., 1989), HAPMO displays no regioselectivity during 
conversion of racemic bicyclohept-2-en-6-one (1). Low ee values have been obtained for the 
different lactones. On the other hand, HAPMO prefers (1R, 5S) bicyclohept-2-en-6-one above the 
(1S, 5R) enantiomer exhibiting an E-value of 20. Therefore, HAPMO can be used for a kinetic 
resolution to obtain the (1S, 5R) enantiomer (Kamerbeek et al., 2003a). 
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 As discussed above for CHMO, several strategies of cofactor regeneration can be employed. In 
biocatalytic applications using isolated enzymes, recycling is commonly achieved by using a 
dehydrogenase. Unfortunately, most of these dehydrogenases are only active with NADH. Clearly, 
a BVMO that would accept NADH as electron donor would be highly interesting for isolated 
enzyme applications. Furthermore, even though whole cells can be used to circumvent the need of a 
coenzyme recycling system, the rate of cellular NADPH recycling might still limit efficient 
catalysis. A change in specificity towards NADH could also be beneficial for biocatalytic 
applications using whole cells as NADH levels in the cell are relatively high (Bochner and Ames, 
1982; Elmore and Porter, 2002). For several flavoproteins a switch in coenzyme specificity has 
been achieved by enzyme engineering (M. H. M. Eppink et al., 1999; Morandi et al., 2000; 
Scrutton et al., 1990), but no Baeyer-Villiger monooxygenase has been engineered for this purpose. 
Recently, we have identified several amino acid residues of HAPMO that are involved in the 
recognition of the 2'-phosphate moiety of NADPH. By changing one of these residues a shift in 
coenzyme preference toward NADH could be established (Kamerbeek et al., 2004). However, the 
observed NADH affinity of the engineered HAPMO variant is still not satisfactory. Clearly, more 
residues need to be changed to improve the NADH specificity in terms of catalytic efficiency. For 
engineering a more effective NADH specific BVMO, a crystal structure of HAPMO or any other 
homologous BVMO would be desirable. 
 
 
3. GENOME HARVESTING OF NOVEL BVMOs 
  
 As described above, the recent effort to discover new Baeyer-Villiger biocatalysts has resulted 
in the identification and sequencing of a number of BVMO genes. Without exception, all novel 
BVMOs could be classified as Type I BVMOs based on their biochemical properties (intracellular, 
soluble, FAD-containing, NADPH dependent, specific activities around 10 U mg-1, subunits of 
typically ~60 kDa) (Table 1). In addition, the sequence information of these novel BVMOs allowed 
a sequence comparison study of Type I BVMOsv (Fraaije et al., 2002). This revealed that Type I 
BVMOs are part of a superfamily of sequence-related flavin dependent monooxygenases. Enzymes 
belonging to this flavoprotein superfamily typically contain two dinucleotide binding sequence 
motifs (GxGxxG/A) which are involved in binding of the cofactor FAD and the coenzyme 
NAD(P)H. All characterized members of this flavoprotein superfamily have indeed been shown to 
be dependent on FAD and require NAD(P)H as electron donor. Based on sequence homology, three 
monooxygenase subfamilies can be recognized within this novel superfamily: (1) the so-called 
FMO family mainly consisting of heteroatom-oxidizing monooxygenases from eukaryotic origin, 
(2) a family of bacterial amine-hydroxylating monooxygenases (NMOs), and (3) a family of Type I 
BVMOs. Interestingly, sequences belonging to the BVMO subfamily could specifically be 
recognized by a strictly conserved sequence motif (FxGxxxHxxxW(P/D) which is not present in 
members from the other two subfamilies (Fraaije et al., 2002). A site-directed mutagenesis study of 
HAPMO showed that residues conserved within this sequence motif are critically involved in 
catalysis. Replacing the strictly conserved histidine in HAPMO by an alanine resulted in an inactive 
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protein while mutagenesis of the conserved tryptophan resulted in impaired protein folding (Fraaije 
et al., 2002). 
 Except for the identification of residues that are of importance to catalyze a Baeyer-Villiger 
reaction, the BVMO-specific fingerprint sequence also helps to identify new BVMO sequences and 
thereby allows efficient harvesting of novel biocatalysts from sequenced genomes. For example, 
genome sequences can be searched for the presence of Type I BVMO sequences. By performing a 
pattern-hit search via the PEDANT database (http://pedant.gsf.de), each available genome can be 
probed for the occurrence of BVMO genes (Table 3). 
 




total number of 
genes 
 
number of Type I  
BVMO genes 
E. coli 4289 0 
M. tubercolosis H37Rv 3924 6 
M. leprae TN 1605 1 
S. coelicolor A3(2) 7512 2 
P. aeruginosa PAO1 5565 3 
S. cerevisae 6449 0 
 
 
 Using this search tool we have found that Type I BVMO genes are present in approximately 
15% of all sequenced microbial genomes. The commonly used hosts for protein expression, E. coli 
and S. cerevisiae, do not contain any Type I BVMO gene. This confirms the suitability of these 
microbial hosts for recombinant BVMO production as they exhibit no competing BVMO activity. 
BVMO genes are frequently found in genomes from pathogenic bacteria including Mycobacterium 
tuberculosis which contains 6 putative BVMO sequences. One of these putative BVMOs has 
recently been reported to be a FAD-containing monooxygenase that is responsible for activation of 
antitubercular drugs by catalyzing a sulfoxidation reaction (Vannelli et al., 2002). We have shown 
that this enzyme is also able to perform Baeyer-Villiger oxidations, suggesting that it indeed 
catalyzes a Baeyer-Villiger reaction in vivo (Fraaije et al. in prep). This is in line with the 
observation that Mycobacteria catalyze a variety of Baeyer-Villiger reactions (Asselineau et al., 
2002; Hartmans and de Bont, 1986). Occurrence of BVMOs is not restricted to bacteria as also 
some BVMO sequences could be identified in genomes from eukaryotic microorganisms like 
Aspergillus parasiticus. In line with this, a Baeyer-Villiger oxidation step has been observed in the 
biosynthesis of aflatoxin by this fungus (Yabe et al., 2003). So far, no Type I BVMO has been 
found in genome sequences from Archaea. This can be explained by the fact that Archaea live in 
extreme environments were oxygen is often not available. Furthermore, no BVMO could be 
identified in the available plant genomes or the human genome. 
 To perform a sequence motif based trawl of multiple genomes, the BVMO-identifying 
sequence motif can be used for a pattern-hit initiated (PHI) BLAST search.(Zhang et al., 1998) 
With such an approach, protein sequences are retrieved that share sequence similarity with known 
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BVMO sequences while they also contain the sequence motif. The latter effectively prevents false 
hits excluding members of the FMO or NMO families. A PHI-BLAST search 
(http://www.ncbi.nlm.nih.gov/BLAST/) performed on December 2nd 2002 yielded a set of 68 
putative microbial BVMO sequences. This set of sequences, including all cloned BVMOs described 
above, mainly consisted of uncharacterized putative BVMO genes. This indicates that a large pool 
of unexplored BVMOs is available for biocatalytic exploration. 
 
 
4. ALTERNATIVE BAEYER-VILLIGER BIOCATALYSTS 
 
 Except for Type I and Type II BVMOs, a small number of other enzymes have been shown to 
catalyze Baeyer-Villiger reactions. One example is the conversion of aromatic aldehydes into the 
corresponding formate esters by a pig liver enzyme (G. P. Chen et al., 1995). This enzyme was 
found to belong to the above-mentioned FMO family and therefore is related to Type I BVMOs 
(Fraaije et al., 2002). As described above, these FMOs share several properties with Type I 
BVMOs. They contain FAD as redox cofactor, use NADPH for activity, and are able to catalyze a 
multitude of oxygenation reactions. Similar to BVMOs, FMOs use the oxygenated flavin as the 
reactive species during catalysis. In mammals FMOs are primarily involved in converting amines 
and other heteroatom containing compounds and serve a role in detoxification similar to 
cytochrome P450 (Ziegler, 2002). While Baeyer-Villiger reactions have only been observed for an 
FMO from pig liver, other FMOs might also be capable of catalyzing Baeyer-Villiger reactions. A 
genome search using a FMO specific fingerprint sequence (Fraaije et al., 2002) revealed that FMO 
genes are abundant in eukaryotic genomes while their number is low in bacterial genomes. Plants 
contain a relatively large number of FMOs and therefore might represent a promising source for 
interesting oxygenating biocatalysts. Interestingly, Baeyer-Villiger oxidation steps have been noted 
in plants (Damtoft et al., 1995; Winter et al., 1999), but it is unknown by which enzyme(s) these 
reactions are catalyzed. 
 Another enzyme that has been shown to catalyze Baeyer-Villiger reactions is the NADH- and 
FMN-dependent luciferase from the light emitting bacterium Vibrio fischeri. This enzyme catalyzes 
the in vivo oxidation of aldehydes into their acids with the concomitant production of light. The 
mechanism for this oxidation reaction was proposed to be similar to a Baeyer-Villiger reaction, 
with formation of a peroxyhemiacetal upon the attack of the peroxyflavin on the substrate (Eckstein 
et al., 1993). Instead of the Baeyer-Villiger rearrangement, a chemically initiated electron 
luminescence (CIEEL) mechanism has been proposed (Eckstein et al., 1993). Nonetheless, the 
enzyme is able to convert bicycloheptenone via a Baeyer-Villiger type of reaction (Villa and 
Willetts, 1997). Being dependent on FMN and NADH Vibrio fischeri luciferase resembles the few 
characterized Type II BVMOs. Whether these BVMOs are related to luciferase will be clarified as 
soon as the first Type II BVMO gene sequence is obtained. 
 Baeyer-Villiger steps have also been reported in the synthesis of polyketides in Streptomyces 
species (Li and Piel, 2002; Prado et al., 1999). Recently, a gene from Streptomyces has been 
identified to catalyze the oxidative cleavage of the premithramycin B at the expense of NADPH and 
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oxygen to form the antitumor drug mithramycin. This ring cleavage reaction is thought to proceed 
via a Baeyer-Villiger mechanism suggesting that the enzyme involved is a BVMO. Interestingly, 
the sequence of the respective enzyme does not contain the Type I BVMO motif and does not share 
significant sequence similarity with any known Type I BVMO. However, it displays some 
similarity with members of another flavoprotein family consisting of FAD-containing hydroxylases 
(M. H. M. Eppink et al., 1997; Orser et al., 1993). Members of this family of monooxygenases also 
rely on the formation of a peroxyflavin intermediate for performing monooxygenation reactions. A 
major difference with Type I BVMOs is the different way of binding their NAD(P)H coenzyme (M. 
H. Eppink et al., 1998; Wang et al., 2002). Another characterized BVMO that can not be classified 
as a Type I or Type II enzyme is the cyclohexanone monooxygenase isolated from a Xanthobacter 
sp. as it is FMN and NADPH dependent (Trower et al., 1989). These examples hint to the existence 
of classes of BVMOs that do not fall into the groups of Type I or Type II BVMOs. 
 
 
5. CONCLUSIONS AND OUTLOOK 
 
 BVMOs are extremely useful enzymes for the environmentally friendly synthesis of esters and 
lactones. The recent characterization of several new BVMOs has expanded the range of enzymatic 
Baeyer-Villiger reactions. Among these enzymes, HAPMO is particularly useful for the conversion 
of aromatic ketones and sulfides, allowing the synthesis of a wide range of phenyl acetates or 
substituted phenols and enantiomerically pure sulfoxides. The recently identified BVMO specific 
sequence motif is a powerful tool to find new BVMOs in the rapidly growing collection of 
sequenced genomes. With the discovery of new BVMOs, new substrates will appear. Combined 
with the rapid development in technologies like high-throughput screening, construction of 
recombinant production organisms and fermentation technology the development of new Baeyer-
Villiger biocatalysts will be greatly facilitated in the near future (Lye et al., 2003).  
 Unfortunately, no BVMO three-dimensional structure is known to date, preventing a 
knowledge-based site-directed mutagenesis approach to re-engineer the biocatalytic properties of a 
specific BVMO. Nonetheless, successful application of random mutagenesis techniques have 
already been reported for a flavoprotein monooxygenase for which structural data are lacking (A. 
Meyer et al., 2002b; A.  Meyer et al., 2002). Therefore, the availability of sequence related BVMO 
genes will allow fine-tuning of catalytic properties by exploiting random mutagenesis and gene 
shuffling methods. Success of such a random enzyme engineering approach relies on efficient 
screening of mutant libraries. For this, a recently reported BVMO specific activity assay can be 
used (Watts et al., 2002). Taken together, the above-mentioned recent developments will enable 
strategies to design tailor-made Baeyer-Villiger biocatalysts in the near future. 
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